Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 Withqs-21 Adjuvant In Japanese Subjects With Mild To Moderate Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2016
At a glance
- Drugs Vanutide cridificar (Primary) ; QS 21
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Pfizer
- 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Oct 2011 Planned end date changed from 1 Jan 2013 to 1 Feb 2013 as reported by ClinicalTrials.gov.
- 17 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.